TargetBeta
MAP2K2
mitogen-activated protein kinase kinase 2 · also MEK2, MKK2, PRKMK2 · Mitogen-activated protein kinase kinases
5 programs in company-led studies act on MAP2K2, from 4 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| cobimetinibrule | Hoffmann-La Roche | inhibitor | phase 3 | 386 running | MAP2K1 | ChEMBL |
| atebimetinibrule | Immuneering | inhibitor | phase 3 | 33 running | – | NCIt |
| mirdametinibrule | Merck KGaA, Darmstadt, Germany | inhibitor | phase 2 | 94 running | MAP2K1 | ChEMBL |
| pimasertibrule | Merck KGaA, Darmstadt, Germany | inhibitor | phase 2 | 130 running | MAP2K1 | NCIt |
| polfurmetinib | Pfizer | inhibitor | phase 1 | 31 running | MAP2K1 | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 3 programs
- Melanoma, 3 programs
- Neoplasms, 3 programs
- Ovarian Neoplasms, 2 programs
- Carcinoma, Hepatocellular, 1 program
- Colorectal Neoplasms, 1 program
- Neoplasm Metastasis, 1 program
- Neurofibroma, Plexiform, 1 program
- Pancreatic Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 27, 2026mirdametinib · Merck KGaA, Darmstadt, Germany · phase 2 · NCT06997276
- Nov 30, 2026cobimetinib · Hoffmann-La Roche · phase 3 · NCT04302025
- Jun 2027atebimetinib · Immuneering · phase 3 · NCT05585320
- Aug 31, 2027polfurmetinib · Pfizer · phase 1 · NCT05538130
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.